U.S. markets close in 4 hours 25 minutes

Novo Nordisk A/S (NVO)

NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
104.25+1.49 (+1.45%)
As of 11:35AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Double Moving Average Crossover

Double Moving Average Crossover

Previous Close102.76
Bid104.11 x 1400
Ask104.26 x 800
Day's Range103.71 - 104.66
52 Week Range91.51 - 122.16
Avg. Volume1,485,219
Market Cap236.612B
Beta (5Y Monthly)0.26
PE Ratio (TTM)34.52
EPS (TTM)3.02
Earnings DateN/A
Forward Dividend & Yield1.61 (1.53%)
Ex-Dividend DateAug 12, 2022
1y Target Est126.70
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Near Fair Value
4% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for NVO

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Novo Nordisk A/S
    Analyst Report: Novo Nordisk A/SWith almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
    Fair Value
    Economic Moat
    15 days agoMorningstar
View more
  • Insider Monkey

    Is Novo Nordisk (NVO) a Smart Long-Term Investment?

    Baron Funds, an asset management firm, published its “Baron Health Care Fund” second quarter 2022 investor letter – a copy of which can be downloaded here. In the quarter ended June 30, 2022, Baron Health Care Fund (the “Fund”) declined 10.00% (Institutional Shares), compared with the 7.43% decline for the Russell 3000 Health Care Index (the […]

  • Motley Fool

    How Eli Lilly Is Thinning Out the Competition

    Pharmaceutical company Eli Lilly (NYSE: LLY) scored a major approval three months ago with its state-of-the-art diabetes drug, Mounjaro. It is too early to tell whether the drug will boost Lilly's sagging revenue, but it does have enormous potential in several huge markets. Early results suggest that the drug could help the company capture crucial share in these key segments.

  • GlobeNewswire

    Novo Nordisk A/S: Share repurchase programme

    Bagsværd, Denmark, 15 August 2022 – On 3 August 2022, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 24 billion to be executed during a 12-month period beginning 2 February 2022. Under the programme in